---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-133381"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T13:48:01.896492+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics appoints Christopher Posner as President and CEO; Derek Chalmers transitions to Senior Advisor

## Summary
- Christopher Posner, former LEO Pharma US CEO and current Cara board member, becomes President and CEO effective Nov 9.
- Derek Chalmers steps down as President, CEO, and director effective Nov 8; will serve as Senior Advisor through June 2022.
- Posner receives $680K base salary, $400K signing bonus, equity awards (566K option shares, 142K RSUs).
- Chalmers receives 12 months base salary, COBRA coverage, 2021 target bonus, and extended equity vesting.
- KORSUVA injection (FDA-approved for pruritus in dialysis) to launch; oral KORSUVA for atopic dermatitis advanced.

## SEC filing metadata
- accession: 0001104659-21-133381
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465921133381/0001104659-21-133381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465921133381/tm2131541d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-133381
- JSON: https://secwatch.observer/filing/0001104659-21-133381.json
- Plain text: https://secwatch.observer/filing/0001104659-21-133381.txt

## Key facts
- Executive change
  Christopher Posner was appointed as President and CEO at Tvardi Therapeutics, Inc..
  - Action: appointed
  - Role: President and CEO
  source text: the appointment of Christopher Posner, age 52, a current non-employee director of the Company, to serve as President and CEO of the Company, effective November 9, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465921133381/0001104659-21-133381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.